05156nam 2201369z- 450 9910367745903321202102113-03921-707-0(CKB)4100000010106258(oapen)https://directory.doabooks.org/handle/20.500.12854/51774(oapen)doab51774(EXLCZ)99410000001010625820202102d2019 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierLinks between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic ChallengesMDPI - Multidisciplinary Digital Publishing Institute20191 online resource (348 p.)3-03921-706-2 Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs.Links between Fibrogenesis and CancerMedicinebicsscacute lung injuryanaplastic lymphoma kinaseangiogenesisantitumor efficacyapoptosisbleomycinbreast cancerbutylidenephthalidecancercancer-associated fibroblastscancer-associated fibroblasts (CAFs)carcinogenesiscirrhosisclinical symptomscommon pathwayscrizotinibcystic formationcytokinecytokinesDHAdiagnosisEMTErk1/2extracellular matrixfibrosisgenetic instabilityGPR120GPR40growth factorHBVHCVhepatic stellate cellshepatic stellate cells (HSCs)hepatocellular carcinomahepatocellular carcinoma (HCC)hepatocytesheterogeneityHippo pathwayidiopathic pulmonary fibrosisidiopathic pulmonary fibrosis (IPF)immunohistochemistryinflammationinterstitial fluid pressureleiomyomaleiomyosarcomalipopolysaccharidelncRNAlung cancerlung cancer (LC)markermechanotransductionmetabolic reprogrammingmetastasismiRNAmyometriumn/ananoparticlesnon-alcoholic steatohepatitisnon-small cell lung cancer (NSCLC)omega-3 fatty acidpathogenesispathologypathophysiologyprotein Spulmonary fibrosisreactive oxygen speciesregenerationrenal injurysignal pathwaySMADsmooth muscle tumor of uncertain malignant potentialSOX2SREBP-1targeted therapyTAZTGF-?therapytransforming growth factor-?tumortumor microenvironmenttumor necrosis factor ?tumor stiffnesstype I collagenuterine fibroidWntYAPMedicineGabazza Esteban Cauth1288168BOOK9910367745903321Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges3020666UNINA